As a result of their deliberations committees may make recommendations which they include in their reports for the consideration of the House of Commons or the Government. Recommendations related to this study are listed below.

Recommendation 1

That the Government of Canada increase its funding for health systems in low-income countries with low vaccine rates and for community-based projects that combat vaccine misinformation and hesitancy.

Recommendation 2

That the Government of Canada increase funding for its Global Initiative for Vaccine Equity.

Recommendation 3

That the Government of Canada make every effort to ensure that Medicago’s COVID-19 vaccine, Covifenz, receives the World Health Organization’s Emergency Use Listing and can be used by the COVAX Facility.

Recommendation 4

That the Government of Canada ensure that any additional funding it provides to the ACT‑Accelerator is more equitably distributed across its four pillars.

Recommendation 5

That the Government of Canada provide additional funding to the South Africa mRNA vaccine technology transfer hub.

Recommendation 6

That the Government of Canada continue to consider the funding it provides to the ACT‑Accelerator as distinct from, and supplementary to, its official development assistance.

Recommendation 7

That, given the increased global needs as a result of the COVID-19 pandemic, the Government of Canada significantly increase its overall contributions to official development assistance in line with the 0.7% of GNI target.

Recommendation 8

That the Government of Canada ensure that its agreements to provide research and development funding include clauses that allow intellectual property resulting from that funding – including vaccines, therapeutics, and diagnostics – to be easily licensed to manufacturers serving low- and middle-income countries.

Recommendation 9

That the Government of Canada advocate for an extension of the June 2022 Ministerial Decision on the TRIPS Agreement to cover the production and supply of COVID-19 diagnostics and therapeutics.

Recommendation 10

That the Government of Canada immediately launch a public consultation on Canada’s Access to Medicines Regime (CAMR) and publish the findings within one year of the tabling of this report in Parliament, and improve its communications and administration related to the CAMR.

Recommendation 11

That the Government of Canada immediately add COVID-19 vaccines, diagnostics, and treatments to Schedule 1 of the Patent Act.